Sms Pharmaceuticals Limited

BSE: 532815 NSE: SMSPHARMA
Sms Pharmaceuticals Limited - pharma in Hyderabad, Telangana, India. FY 2026 financials and compliance.
CIN L24239TG1987PLC008066 Incorporated 14 December 1987 ROC Hyderabad HQ Hyderabad, Telangana, India
Active Listed - NSE: SMSPHARMA · BSE: 532815 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹886.87 Cr
▲ 13.3% YoY
EBITDA · FY 2026
₹179.63 Cr
▲ 23.7% YoY
Net profit · FY 2026
₹101.99 Cr
▲ 47.52% YoY
Authorised capital
₹12 Cr
Registered with MCA
Paid-up capital
₹9.37 Cr
Issued & subscribed
Open charges
₹600.28 Cr
Satisfied ₹640.7 Cr
Company age
39 yrs
Est. 1987
Employees · EPFO
1,193
Latest available

About Sms Pharmaceuticals Limited

Data last updated: 11 January 2026

Sms Pharmaceuticals Limited is a public limited company based in Hyderabad, Telangana, India. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 14 December 1987, the company has been in operation for over 39 years.

Registered with ROC Hyderabad under CIN L24239TG1987PLC008066. Listed on BSE: 532815 and NSE: SMSPHARMA.

Capital: an authorised share capital of ₹12 Cr and a paid-up capital of ₹9.37 Cr. Formerly known as S.M.S. Pharmaceuticals Private Limited and Sms Pharmaceuticals Pvt Limited. It is led by directors including Srinivas Sarvepalli and Vamsi Krishna Potluri.

Last AGM: 29 September 2025. Financial statements filed for year ended 31 March 2025. Office: Hyderabad, Telangana.

As per the financials filed for FY 2025, the company reported a revenue of ₹788.97 Cr, a growth of 11% compared to the previous year.

The company has a workforce of approximately 1,193 employees as per the latest available data.

The company is associated with 1 brand - Sms Pharmaceuticals. As per MCA filings, the company has open charges of ₹600.28 Cr and satisfied charges of ₹640.7 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website smspharma.com.

Company Details of Sms Pharmaceuticals Limited
CIN L24239TG1987PLC008066
Registration Number 008066
Incorporation Date 14 December 1987
ROC Hyderabad
Listing Status Listed (BSE: 532815, NSE: SMSPHARMA)
Company Status Active
Date of Last AGM 29 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Ramesh Babu Potluri Managing Director Vamsi Krishna Potluri Whole-Time Director Srinivas Sarvepalli Director
Contact Details
  • Email
    *****@*****.com
  • Telephone
    +91-****-******
  • Website
    smspharma.com
  • Social Media
    **************
  • Registered Address
    Plot No. 72 H.No: 8 – 2 – 334/3&4 Road No. 5 Opp. Sbi Executive Enclave Banjara Hill, S, Hyderabad, Telangana, India – 500034
  • Industry
    Pharma, API Manufacturers
Company report
Sms Pharmaceuticals Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Sms Pharmaceuticals Limited report

Financials, compliance, directors, charges, ownership and filings for Sms Pharmaceuticals Limited in one report.

10-year financials Directors & ownership Charges & compliance

Name History of Sms Pharmaceuticals Limited

Sms Pharmaceuticals Limited has undergone 2 name changes throughout its history. The company was previously known as S.M.S. Pharmaceuticals Private Limited, and Sms Pharmaceuticals Pvt Limited. The current legal name is Sms Pharmaceuticals Limited, reflecting the company's evolution and rebranding over time.

Company Name Status
Sms Pharmaceuticals Limited Current
S.M.S. Pharmaceuticals Private Limited Previous
Sms Pharmaceuticals Pvt Limited Previous

CIN History of Sms Pharmaceuticals Limited

Sms Pharmaceuticals Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24239TG1987PLC008066, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24239TG1987PLC008066 Current
U24239AP1987PLC008066 Previous
L24239AP1987PLC008066 Previous

Associated Brands with Sms Pharmaceuticals Limited

Sms Pharmaceuticals Limited operates one associated brand: Sms Pharmaceuticals. These brands represent Sms Pharmaceuticals Limited's diversified market presence and brand portfolio.

Brand Description Website
Sms Pharmaceuticals
Active pharmaceutical ingredients and intermediates are manufactured by SMS Pharmaceuticals. smspharma.com

Competitors & Alternatives of Sms Pharmaceuticals Limited

Brands and companies operating in the same space as Sms Pharmaceuticals Limited include Laurus Labs, Symbiotec, Beijing Biostar Technologies and 6 more.

Competitor Description Location Founded
Laurus Labs Laurus Labs Pharmaceutical and biotechnology company Hyderabad, India, India 2005
Symbiotec Symbiotec Non-sterile steroid hormone-based APIs and intermediates are manufactured. Indore, India, India 2002
Beijing Biostar Technologies Beijing Biostar Technologies APIs, intermediates, and biochemical reagents are developed and manufactured. Beijing, China, China 2002
Sterling Pharma Solutions Sterling Pharma Solutions Contract development, manufacturing, and analytical services for APIs are offered. Dudley, United Kingdom, United Kingdom 2016
Provepharm Life Solutions Provepharm Life Solutions APIs and drug products are developed and valorized in pharmaceuticals. Marseille, France, France 1998
Hikal Hikal APIs and intermediates are produced via custom synthesis and research. Mumbai, India, India 1988
Snapdragon Chemistry Snapdragon Chemistry Drug discovery and development service provider Cambridge, United States, United States 2014
SeQuent SeQuent APIs are developed and manufactured for therapeutic areas. Bengaluru, India, India 2002
Jubilant Pharma Jubilant Pharma Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company. Noida, India, India 1978

Business Activity of Sms Pharmaceuticals Limited

Sms Pharmaceuticals Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products *********

Auditor Details of Sms Pharmaceuticals Limited

Sms Pharmaceuticals Limited is audited by M/s.Suryanarayana & Suresh, Chartered Accountants (ICAI peer reviewed, certificate valid till 2026-07-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
M/s.Suryanarayana & Suresh, Chartered Accountants (ICAI peer reviewed, certificate valid till 2026-07-31) FY 2026 Declaration of unmodified opinion

Board of Directors of Sms Pharmaceuticals Limited

Sms Pharmaceuticals Limited is currently managed by 10 directors, with 28 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Srinivas Sarvepalli Director 12 Aug 2019 6 Years 10 Months Current
Vamsi Krishna Potluri
Also directs: Sms Peptides Private Limited, Vkt Pharma Private Limited, Potluri Infra Projects Llp and 3 more
Whole-Time Director 05 Jun 2020 6 Years 1 Months Current
Shravan Kudaravalli
Also directs: Cmh Tools Limited
Director 26 May 2018 8 Years 1 Months Current
Ramesh Babu Potluri
Also directs: Potluri Agri Farms Llp, Sms Peptides Private Limited, Vkt Pharma Private Limited and 1 more
Managing Director 01 Dec 2008 17 Years 7 Months Current
Trilok Potluri
Also directs: Potluri Infra Projects Llp, Tvt Infracon Llp, Gentides Pharma Private Limited and 3 more
Director 12 Aug 2024 1 Years 10 Months Current
Shanti Sree Bolleni
Also directs: Tukaram & Co Llp, Rain Industries Limited, Nile Limited and 5 more
Director 12 Aug 2024 1 Years 10 Months Current
Showing 6 of 10 current directors. View all directors

Financials of Sms Pharmaceuticals Limited FY 2026 filings available

Sms Pharmaceuticals Limited reported revenue of ₹886.87 Cr (up 13.3% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.

Revenue · FY 2026
₹886.87 Cr ▲ 13.3%
Profit · FY 2026
₹101.99 Cr ▲ 47.52%
EBITDA · FY 2026
₹179.63 Cr ▲ 23.7%
Revenue₹ Cr · Consolidated05001,000FY 2020: ₹412 Cr412FY 2020FY 2021: ₹563 Cr · +36.7% YoY563+36.7%FY 2021FY 2022: ₹520 Cr · -7.7% YoY520-7.7%FY 2022FY 2023: ₹522 Cr · +0.4% YoY522+0.4%FY 2023FY 2024: ₹709 Cr · +35.9% YoY709+35.9%FY 2024FY 2025: ₹783 Cr · +10.4% YoY783+10.4%FY 2025FY 2026: ₹887 Cr · +13.3% YoY887+13.3%FY 2026
Net Profit₹ Cr · Consolidated-50050100150FY 2020: ₹33 Cr32.7FY 2020FY 2021: ₹63 Cr · +91.3% YoY62.5+91.3%FY 2021FY 2022: ₹62 Cr · -0.5% YoY62.2-0.5%FY 2022FY 2023: ₹7 Cr (loss) · -111.3% YoY-7.1FY 2023FY 2024: ₹50 Cr · +805.8% YoY49.8+805.8%FY 2024FY 2025: ₹69 Cr · +38.8% YoY69.1+38.8%FY 2025FY 2026: ₹102 Cr · +47.5% YoY102+47.5%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year0100200300Q1'25: ₹164 Cr · +21.5% YoY164+21.5%Q1'25Q2'25: ₹197 Cr · +18.1% YoY197+18.1%Q2'25Q3'25: ₹173 Cr · +7.4% YoY173+7.4%Q3'25Q4'25: ₹248 Cr · +1% YoY248+1%Q4'25Q1'26: ₹196 Cr · +19.2% YoY196+19.2%Q1'26Q2'26: ₹242 Cr · +23.2% YoY242+23.2%Q2'26Q3'26: ₹210 Cr · +21.4% YoY210+21.4%Q3'26Q4'26: ₹238 Cr · -4.1% YoY238-4.1%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹886.87 Cr ₹782.75 Cr ₹709.26 Cr ₹522.05 Cr ₹519.87 Cr ₹563.18 Cr ₹411.95 Cr
Other Income ₹8.35 Cr ₹6.22 Cr ₹4.46 Cr ₹4.89 Cr ₹5.2 Cr ₹3.45 Cr ₹5.11 Cr
Total Income ₹895.22 Cr ₹788.97 Cr ₹713.72 Cr ₹526.94 Cr ₹525.07 Cr ₹566.63 Cr ₹417.06 Cr
Cost of Materials Consumed ₹516.44 Cr ₹501.87 Cr ₹425.26 Cr ₹299.73 Cr ₹387.95 Cr ₹313.27 Cr ₹259.5 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories -₹23.09 Cr -₹64.81 Cr -₹1 Cr ₹36.08 Cr -₹112.5 Cr ₹26.73 Cr -₹13.14 Cr
Employee Benefit Expense ₹87.96 Cr ₹80.08 Cr ₹64.15 Cr ₹55.04 Cr ₹51.02 Cr ₹41.17 Cr ₹39.35 Cr
Finance Costs ₹23.08 Cr ₹18.54 Cr ₹23.46 Cr ₹21.92 Cr ₹18.88 Cr ₹11.16 Cr ₹12.21 Cr
Depreciation & Amortisation ₹39.92 Cr ₹34.34 Cr ₹31.52 Cr ₹32.13 Cr ₹32.15 Cr ₹22.28 Cr ₹22.07 Cr
Other Expenses ₹134.29 Cr ₹126.61 Cr ₹104.23 Cr ₹76.69 Cr ₹79.07 Cr ₹60.9 Cr ₹46.31 Cr
Total Expenses ₹778.59 Cr ₹696.64 Cr ₹647.62 Cr ₹521.59 Cr ₹456.57 Cr ₹475.51 Cr ₹366.3 Cr
Profit Before Exceptional Items & Tax ₹116.64 Cr ₹92.34 Cr ₹66.11 Cr ₹5.35 Cr ₹68.5 Cr ₹91.12 Cr ₹50.76 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹116.64 Cr ₹92.34 Cr ₹66.11 Cr ₹5.35 Cr ₹68.5 Cr ₹91.12 Cr ₹50.76 Cr
Total Tax Expense ₹28.64 Cr ₹24.94 Cr ₹16.91 Cr ₹1.47 Cr ₹61.82 Lakh ₹30.16 Cr ₹18.07 Cr
Net Profit ₹101.99 Cr ₹69.14 Cr ₹49.83 Cr -₹7.06 Cr ₹62.22 Cr ₹62.53 Cr ₹32.69 Cr
  attributable to Owners ₹102.09 Cr ₹68.61 Cr ₹0 ₹0 - - ₹0
  attributable to NCI ₹0 ₹0 ₹0 ₹0 - - ₹0
Other Comprehensive Income ₹10.06 Lakh -₹52.45 Lakh ₹6.74 Lakh -₹16.45 Lakh ₹8.01 Lakh -₹23.44 Lakh ₹15.28 Lakh
Total Comprehensive Income ₹102.09 Cr ₹68.61 Cr ₹49.89 Cr -₹7.22 Cr ₹62.3 Cr ₹62.29 Cr ₹32.84 Cr
EBITDA (computed) ₹179.63 Cr ₹145.22 Cr ₹121.08 Cr ₹59.39 Cr ₹119.53 Cr ₹124.56 Cr ₹85.03 Cr
Basic EPS ₹11.15 ₹8.16 ₹5.89 ₹-0.83 ₹7.35 ₹7.39 ₹3.73
Diluted EPS ₹11.15 ₹8.16 ₹5.89 ₹0.00 ₹7.35 ₹7.39 ₹3.73
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹1,362.44 Cr ₹1,152.68 Cr ₹1,034.09 Cr ₹879.61 Cr
Non-current Assets ₹724.43 Cr ₹598.21 Cr ₹500.2 Cr ₹468.96 Cr
Current Assets ₹638.01 Cr ₹554.47 Cr ₹533.89 Cr ₹410.65 Cr
Property, Plant & Equipment ₹531.22 Cr ₹530.85 Cr ₹434.19 Cr ₹409.5 Cr
Inventories ₹351.21 Cr ₹284.73 Cr ₹233.7 Cr ₹223.5 Cr
Trade Receivables ₹215.87 Cr ₹203.23 Cr ₹236.23 Cr ₹148.35 Cr
Cash & Equivalents ₹45.88 Cr ₹41.4 Cr ₹36.04 Cr ₹7.38 Cr
Equity (Net Worth) ₹785.81 Cr ₹639.64 Cr ₹536.33 Cr ₹460.53 Cr
Equity Share Capital ₹9.37 Cr ₹8.87 Cr ₹8.47 Cr ₹8.47 Cr
Borrowings (Non-current) ₹171.64 Cr ₹139.36 Cr ₹122.09 Cr ₹121.13 Cr
Borrowings (Current) ₹193.41 Cr ₹171.39 Cr ₹158.09 Cr ₹131.38 Cr
Total Debt (computed) ₹365.05 Cr ₹310.76 Cr ₹280.18 Cr ₹252.51 Cr
Current Liabilities ₹352.98 Cr ₹324.37 Cr ₹331.72 Cr ₹254.91 Cr
Total Liabilities ₹576.63 Cr ₹513.04 Cr ₹497.76 Cr ₹419.08 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹59.22 Cr ₹81.71 Cr ₹50.12 Cr ₹22.45 Cr ₹40.23 Cr
Investing Cash Flow -₹130.78 Cr -₹123.43 Cr -₹52.07 Cr -₹29.69 Cr -₹27.15 Cr
Financing Cash Flow ₹76.03 Cr ₹47.08 Cr ₹30.68 Cr -₹31.97 Cr -₹6.92 Cr
Capital Expenditure ₹130.56 Cr ₹123.38 Cr ₹52.16 Cr ₹29.92 Cr ₹27.25 Cr
Free Cash Flow (computed) -₹71.33 Cr -₹41.67 Cr -₹2.04 Cr -₹7.47 Cr ₹12.99 Cr
Dividends Paid ₹3.55 Cr ₹3.39 Cr ₹2.54 Cr ₹2.54 Cr ₹2.54 Cr
Net Change in Cash ₹4.48 Cr ₹5.36 Cr ₹28.73 Cr -₹39.21 Cr ₹6.16 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹237.95 Cr ₹210.45 Cr ₹242.43 Cr ₹196.05 Cr ₹248.2 Cr ₹173.35 Cr ₹196.75 Cr ₹164.45 Cr ₹245.8 Cr ₹161.48 Cr ₹166.64 Cr ₹135.34 Cr
Other Income ₹2.57 Cr ₹3.75 Cr ₹1.43 Cr ₹59.31 Lakh ₹1.42 Cr ₹2.13 Cr ₹1.3 Cr ₹1.37 Cr ₹1.65 Cr ₹1.49 Cr ₹81.03 Lakh ₹51.29 Lakh
Total Income ₹240.52 Cr ₹214.2 Cr ₹243.86 Cr ₹196.64 Cr ₹249.62 Cr ₹175.48 Cr ₹198.05 Cr ₹165.82 Cr ₹247.44 Cr ₹162.97 Cr ₹167.45 Cr ₹135.85 Cr
Cost of Materials Consumed ₹128.46 Cr ₹139.19 Cr ₹106.56 Cr ₹146.66 Cr ₹117.54 Cr ₹118.32 Cr ₹158.77 Cr ₹107.24 Cr ₹97.47 Cr ₹132.48 Cr ₹103.59 Cr ₹91.72 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories ₹4.76 Cr -₹25.43 Cr ₹33.26 Cr -₹35.69 Cr ₹30.37 Cr -₹32.83 Cr -₹43.08 Cr -₹19.28 Cr ₹63.22 Cr -₹41.22 Cr -₹5.78 Cr -₹17.22 Cr
Employee Benefit Expense ₹29.47 Cr ₹21.05 Cr ₹19.25 Cr ₹18.18 Cr ₹26.63 Cr ₹18.64 Cr ₹17.93 Cr ₹16.88 Cr ₹20.12 Cr ₹14.02 Cr ₹13.65 Cr ₹13.55 Cr
Finance Costs ₹5.28 Cr ₹6.22 Cr ₹5.74 Cr ₹5.84 Cr ₹5.07 Cr ₹4.2 Cr ₹4.61 Cr ₹4.67 Cr ₹5.61 Cr ₹5.95 Cr ₹5.57 Cr ₹6.32 Cr
Depreciation & Amortisation ₹10.13 Cr ₹10.02 Cr ₹10.02 Cr ₹9.75 Cr ₹8.64 Cr ₹8.7 Cr ₹8.62 Cr ₹8.38 Cr ₹7.92 Cr ₹8.01 Cr ₹7.9 Cr ₹7.69 Cr
Other Expenses ₹35.36 Cr ₹31.98 Cr ₹34.99 Cr ₹27.52 Cr ₹32.85 Cr ₹36.01 Cr ₹31.66 Cr ₹26.09 Cr ₹31.36 Cr ₹27.21 Cr ₹27.36 Cr ₹21.1 Cr
Total Expenses ₹213.46 Cr ₹183.04 Cr ₹209.82 Cr ₹172.27 Cr ₹221.09 Cr ₹153.04 Cr ₹178.51 Cr ₹143.99 Cr ₹225.71 Cr ₹146.45 Cr ₹152.29 Cr ₹123.17 Cr
Profit Before Exceptional Items & Tax ₹27.07 Cr ₹31.16 Cr ₹34.04 Cr ₹24.37 Cr ₹28.52 Cr ₹22.44 Cr ₹19.54 Cr ₹21.83 Cr ₹21.74 Cr ₹16.53 Cr ₹15.16 Cr ₹12.68 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹27.07 Cr ₹31.16 Cr ₹34.04 Cr ₹24.37 Cr ₹28.52 Cr ₹22.44 Cr ₹19.54 Cr ₹21.83 Cr ₹21.74 Cr ₹16.53 Cr ₹15.16 Cr ₹12.68 Cr
Total Tax Expense ₹6.1 Cr ₹7.97 Cr ₹8.91 Cr ₹5.65 Cr ₹8.44 Cr ₹5.36 Cr ₹5.68 Cr ₹5.46 Cr ₹5.69 Cr ₹4.24 Cr ₹3.11 Cr ₹3.87 Cr
Net Profit ₹32.71 Cr ₹23.47 Cr ₹25.31 Cr ₹20.49 Cr ₹20.31 Cr ₹18.24 Cr ₹14.1 Cr ₹16.48 Cr ₹17.28 Cr ₹11.48 Cr ₹11.73 Cr ₹9.34 Cr
  attributable to Owners ₹33 Cr ₹23.47 Cr ₹25.31 Cr - ₹119.73 Cr ₹18.26 Cr ₹0 ₹0 ₹0 ₹11.42 Cr ₹0 ₹0
  attributable to NCI ₹0 ₹0 ₹0 - ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 -
Other Comprehensive Income ₹28.25 Lakh -₹59,000 -₹8.79 Lakh -₹8.8 Lakh -₹58.16 Lakh ₹1.9 Lakh ₹4.87 Lakh -₹1.07 Lakh ₹22.15 Lakh -₹5.64 Lakh -₹5.12 Lakh -₹4.64 Lakh
Total Comprehensive Income ₹33 Cr ₹23.47 Cr ₹25.22 Cr ₹20.4 Cr ₹19.73 Cr ₹18.26 Cr ₹14.15 Cr ₹16.47 Cr ₹17.5 Cr ₹11.42 Cr ₹11.67 Cr ₹9.3 Cr
EBITDA (computed) ₹42.47 Cr ₹47.4 Cr ₹49.8 Cr ₹39.96 Cr ₹42.23 Cr ₹35.34 Cr ₹32.77 Cr ₹34.88 Cr ₹35.26 Cr ₹30.49 Cr ₹28.63 Cr ₹26.7 Cr
Basic EPS ₹3.58 ₹2.59 ₹2.84 ₹2.31 ₹2.40 ₹2.15 ₹1.69 ₹1.95 ₹2.04 ₹1.36 ₹1.39 ₹1.10
Diluted EPS ₹3.58 ₹2.59 ₹2.84 ₹2.31 ₹2.40 ₹2.15 ₹1.69 ₹1.95 ₹2.04 ₹1.36 ₹1.39 ₹1.10
Latest 12 quarters shown of 25 on record.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹886.87 Cr ₹782.75 Cr ₹709.26 Cr ₹522.05 Cr ₹519.87 Cr ₹563.18 Cr ₹411.95 Cr
Other Income ₹8.35 Cr ₹6.22 Cr ₹4.46 Cr ₹4.89 Cr ₹5.2 Cr ₹3.45 Cr ₹5.11 Cr
Total Income ₹895.22 Cr ₹788.97 Cr ₹713.72 Cr ₹526.94 Cr ₹525.07 Cr ₹566.63 Cr ₹417.06 Cr
Cost of Materials Consumed ₹516.87 Cr ₹500.9 Cr ₹425.04 Cr ₹299.53 Cr ₹387.8 Cr ₹313.27 Cr ₹259.5 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories -₹22.84 Cr -₹64.81 Cr -₹1 Cr ₹36.08 Cr -₹112.5 Cr ₹26.73 Cr -₹13.14 Cr
Employee Benefit Expense ₹87.92 Cr ₹80.08 Cr ₹64.15 Cr ₹55.04 Cr ₹51.02 Cr ₹41.17 Cr ₹39.35 Cr
Finance Costs ₹23.08 Cr ₹18.54 Cr ₹23.46 Cr ₹21.92 Cr ₹18.88 Cr ₹11.16 Cr ₹12.21 Cr
Depreciation & Amortisation ₹39.92 Cr ₹34.34 Cr ₹31.52 Cr ₹32.13 Cr ₹32.15 Cr ₹22.28 Cr ₹22.07 Cr
Other Expenses ₹134 Cr ₹126.61 Cr ₹104.23 Cr ₹76.69 Cr ₹79.07 Cr ₹60.9 Cr ₹46.31 Cr
Total Expenses ₹778.95 Cr ₹695.65 Cr ₹647.39 Cr ₹521.39 Cr ₹456.42 Cr ₹475.51 Cr ₹366.3 Cr
Profit Before Exceptional Items & Tax ₹116.27 Cr ₹93.32 Cr ₹66.33 Cr ₹5.55 Cr ₹68.65 Cr ₹91.12 Cr ₹50.76 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹116.27 Cr ₹93.32 Cr ₹66.33 Cr ₹5.55 Cr ₹68.65 Cr ₹91.12 Cr ₹50.76 Cr
Total Tax Expense ₹28.66 Cr ₹24.94 Cr ₹16.91 Cr ₹1.47 Cr ₹61.82 Lakh ₹30.16 Cr ₹18.07 Cr
Net Profit ₹87.61 Cr ₹68.38 Cr ₹49.42 Cr ₹4.08 Cr ₹68.04 Cr ₹60.96 Cr ₹32.69 Cr
Other Comprehensive Income ₹3.31 Lakh -₹50.35 Lakh ₹5.27 Lakh -₹20.53 Lakh ₹3.93 Lakh -₹16.46 Lakh ₹8.56 Lakh
Total Comprehensive Income ₹87.64 Cr ₹67.88 Cr ₹49.48 Cr ₹3.88 Cr ₹68.08 Cr ₹60.8 Cr ₹32.77 Cr
EBITDA (computed) ₹179.27 Cr ₹146.2 Cr ₹121.3 Cr ₹59.59 Cr ₹119.68 Cr ₹124.56 Cr ₹85.03 Cr
Basic EPS ₹9.58 ₹8.07 ₹5.84 ₹0.48 ₹8.04 ₹7.20 ₹3.86
Diluted EPS ₹9.58 ₹8.07 ₹5.84 ₹0.48 ₹8.04 ₹7.20 ₹3.86
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹1,381 Cr ₹1,186.1 Cr ₹1,068.25 Cr ₹914.18 Cr
Non-current Assets ₹744.43 Cr ₹631.64 Cr ₹534.36 Cr ₹503.54 Cr
Current Assets ₹636.57 Cr ₹554.46 Cr ₹533.89 Cr ₹410.65 Cr
Property, Plant & Equipment ₹531.22 Cr ₹530.85 Cr ₹434.19 Cr ₹409.5 Cr
Inventories ₹350.95 Cr ₹284.73 Cr ₹233.7 Cr ₹223.5 Cr
Trade Receivables ₹215.88 Cr ₹203.23 Cr ₹236.23 Cr ₹148.35 Cr
Cash & Equivalents ₹45.78 Cr ₹41.39 Cr ₹36.04 Cr ₹7.38 Cr
Equity (Net Worth) ₹804.79 Cr ₹673.07 Cr ₹570.49 Cr ₹495.1 Cr
Equity Share Capital ₹9.37 Cr ₹8.87 Cr ₹8.47 Cr ₹8.47 Cr
Borrowings (Non-current) ₹171.64 Cr ₹139.36 Cr ₹122.09 Cr ₹121.13 Cr
Borrowings (Current) ₹193.41 Cr ₹171.39 Cr ₹158.09 Cr ₹131.38 Cr
Total Debt (computed) ₹365.05 Cr ₹310.76 Cr ₹280.18 Cr ₹252.51 Cr
Current Liabilities ₹352.54 Cr ₹324.36 Cr ₹331.72 Cr ₹254.91 Cr
Total Liabilities ₹576.21 Cr ₹513.03 Cr ₹497.76 Cr ₹419.08 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹60.68 Cr ₹81.71 Cr ₹50.12 Cr ₹22.45 Cr ₹40.23 Cr
Investing Cash Flow -₹132.33 Cr -₹123.44 Cr -₹52.07 Cr -₹29.69 Cr -₹27.15 Cr
Financing Cash Flow ₹76.03 Cr ₹47.08 Cr ₹30.68 Cr -₹31.97 Cr -₹6.92 Cr
Capital Expenditure ₹125.11 Cr ₹123.38 Cr ₹52.16 Cr ₹29.92 Cr ₹27.25 Cr
Free Cash Flow (computed) -₹64.42 Cr -₹41.67 Cr -₹2.04 Cr -₹7.47 Cr ₹12.99 Cr
Dividends Paid ₹3.55 Cr ₹3.39 Cr ₹2.54 Cr ₹2.54 Cr ₹2.54 Cr
Net Change in Cash ₹4.39 Cr ₹5.35 Cr ₹28.73 Cr -₹39.21 Cr ₹6.16 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹237.95 Cr ₹210.45 Cr ₹242.43 Cr ₹196.05 Cr ₹248.2 Cr ₹173.35 Cr ₹196.75 Cr ₹164.45 Cr ₹245.8 Cr ₹161.48 Cr ₹166.64 Cr ₹135.34 Cr
Other Income ₹2.57 Cr ₹3.75 Cr ₹1.43 Cr ₹59.31 Lakh ₹1.42 Cr ₹2.13 Cr ₹1.3 Cr ₹1.37 Cr ₹1.65 Cr ₹1.49 Cr ₹81.03 Lakh ₹51.29 Lakh
Total Income ₹240.52 Cr ₹214.2 Cr ₹243.86 Cr ₹196.64 Cr ₹249.62 Cr ₹175.48 Cr ₹198.05 Cr ₹165.82 Cr ₹247.44 Cr ₹162.97 Cr ₹167.45 Cr ₹135.85 Cr
Cost of Materials Consumed ₹128.31 Cr ₹139.13 Cr ₹106.58 Cr ₹147.29 Cr ₹117.01 Cr ₹118.22 Cr ₹158.38 Cr ₹107.29 Cr ₹97.6 Cr ₹132.6 Cr ₹103.59 Cr ₹91.25 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories ₹5.01 Cr -₹25.43 Cr ₹33.26 Cr -₹35.69 Cr ₹30.37 Cr -₹32.83 Cr -₹43.08 Cr -₹19.28 Cr ₹63.22 Cr -₹41.22 Cr -₹5.78 Cr -₹17.22 Cr
Employee Benefit Expense ₹29.43 Cr ₹21.05 Cr ₹19.25 Cr ₹18.18 Cr ₹26.63 Cr ₹18.64 Cr ₹17.93 Cr ₹16.88 Cr ₹20.12 Cr ₹14.02 Cr ₹13.65 Cr ₹13.55 Cr
Finance Costs ₹5.28 Cr ₹6.22 Cr ₹5.74 Cr ₹5.84 Cr ₹5.07 Cr ₹4.2 Cr ₹4.61 Cr ₹4.67 Cr ₹5.61 Cr ₹5.95 Cr ₹5.57 Cr ₹6.32 Cr
Depreciation & Amortisation ₹10.13 Cr ₹10.02 Cr ₹10.02 Cr ₹9.75 Cr ₹8.64 Cr ₹8.7 Cr ₹8.62 Cr ₹8.38 Cr ₹7.92 Cr ₹8.01 Cr ₹7.9 Cr ₹7.69 Cr
Other Expenses ₹35.31 Cr ₹31.9 Cr ₹34.95 Cr ₹27.4 Cr ₹32.84 Cr ₹36.01 Cr ₹31.66 Cr ₹26.09 Cr ₹31.36 Cr ₹27.21 Cr ₹27.36 Cr ₹21.1 Cr
Total Expenses ₹213.48 Cr ₹182.89 Cr ₹209.81 Cr ₹172.78 Cr ₹220.56 Cr ₹152.95 Cr ₹178.11 Cr ₹144.04 Cr ₹225.84 Cr ₹146.57 Cr ₹152.29 Cr ₹122.7 Cr
Profit Before Exceptional Items & Tax ₹27.05 Cr ₹31.31 Cr ₹34.06 Cr ₹23.86 Cr ₹29.06 Cr ₹22.53 Cr ₹19.94 Cr ₹21.78 Cr ₹21.61 Cr ₹16.41 Cr ₹15.16 Cr ₹13.16 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹27.05 Cr ₹31.31 Cr ₹34.06 Cr ₹23.86 Cr ₹29.06 Cr ₹22.53 Cr ₹19.94 Cr ₹21.78 Cr ₹21.61 Cr ₹16.41 Cr ₹15.16 Cr ₹13.16 Cr
Total Tax Expense ₹6.12 Cr ₹7.97 Cr ₹8.91 Cr ₹5.65 Cr ₹8.44 Cr ₹5.36 Cr ₹5.68 Cr ₹5.46 Cr ₹5.69 Cr ₹4.24 Cr ₹3.11 Cr ₹3.87 Cr
Net Profit ₹20.92 Cr ₹23.34 Cr ₹25.14 Cr ₹18.21 Cr ₹20.62 Cr ₹17.17 Cr ₹14.26 Cr ₹16.33 Cr ₹15.92 Cr ₹12.17 Cr ₹12.05 Cr ₹9.28 Cr
Other Comprehensive Income ₹23.44 Lakh -₹1.24 Lakh -₹9.44 Lakh -₹9.44 Lakh -₹54.9 Lakh ₹1.51 Lakh ₹4.48 Lakh -₹1.45 Lakh ₹23.75 Lakh -₹6.67 Lakh -₹6.16 Lakh -₹5.64 Lakh
Total Comprehensive Income ₹21.16 Cr ₹23.33 Cr ₹25.05 Cr ₹18.11 Cr ₹20.07 Cr ₹17.19 Cr ₹14.3 Cr ₹16.31 Cr ₹16.16 Cr ₹12.11 Cr ₹11.99 Cr ₹9.23 Cr
EBITDA (computed) ₹42.45 Cr ₹47.55 Cr ₹49.81 Cr ₹39.45 Cr ₹42.77 Cr ₹35.43 Cr ₹33.17 Cr ₹34.83 Cr ₹35.13 Cr ₹30.37 Cr ₹28.63 Cr ₹27.17 Cr
Basic EPS ₹2.29 ₹2.57 ₹2.82 ₹2.05 ₹2.43 ₹2.03 ₹1.68 ₹1.93 ₹1.88 ₹1.44 ₹1.42 ₹1.10
Diluted EPS ₹2.29 ₹2.57 ₹2.82 ₹2.05 ₹2.43 ₹2.03 ₹1.68 ₹1.93 ₹1.88 ₹1.44 ₹1.42 ₹1.10
Latest 12 quarters shown of 25 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Sms Pharmaceuticals Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Sms Pharmaceuticals Limited

As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 68.07%, foreign institutional investors hold 0.31%, domestic institutional investors hold 3.02%, retail and other public shareholders hold 28.60% of Sms Pharmaceuticals Limited. The company had 32,397 shareholders on record.

Promoters: 68.07%DII (Domestic Institutional): 3.02%FII (Foreign Institutional): 0.31%Retail & Others: 28.60%
Mar 2026
QUARTER
68.07% Promoters
3.02% DII (Domestic Institutional)
0.31% FII (Foreign Institutional)
28.60% Retail & Others
Promoter holding - history
Now 68.07% · Mar 2026High 68.07% · Sep 2025Low 63.88% · Dec 2015
62%64%66%68%70%Dec 2015Jun 2018Dec 2020Jun 2023Dec 2025Dec 2015: 63.88%Mar 2016: 63.88%Jun 2016: 63.88%Sep 2016: 63.88%Dec 2016: 67.60%Mar 2017: 67.60%Jun 2017: 67.99%Sep 2017: 67.99%Dec 2017: 67.27%Mar 2018: 67.27%Jun 2018: 67.27%Sep 2018: 67.27%Dec 2018: 67.27%Mar 2019: 67.27%Jun 2019: 67.27%Sep 2019: 67.29%Dec 2019: 67.29%Mar 2020: 67.29%Jun 2020: 67.29%Sep 2020: 67.29%Dec 2020: 67.29%Mar 2021: 67.29%Jun 2021: 67.29%Sep 2021: 67.29%Dec 2021: 67.29%Mar 2022: 67.29%Jun 2022: 64.17%Sep 2022: 64.17%Dec 2022: 64.17%Mar 2023: 64.29%Jun 2023: 64.32%Sep 2023: 64.32%Dec 2023: 64.32%Mar 2024: 64.67%Jun 2024: 64.67%Sep 2024: 64.67%Dec 2024: 64.67%Mar 2025: 66.26%Jun 2025: 66.26%Sep 2025: 68.07%Dec 2025: 68.07%Mar 2026: 68.07%68.07%63.88%68.07%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters68.07%68.07%68.07%66.26%66.26%64.67%
Public31.93%31.93%31.93%33.74%33.74%35.33%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Promoters68.07%66.26%64.67%64.29%67.29%67.29%67.29%67.27%67.27%67.60%63.88%
Public31.93%33.74%35.33%35.71%32.71%32.71%32.71%32.73%32.73%32.40%36.12%
Promoter change (YoY, %pts)+1.81+1.59+0.38-3.00+0.00+0.00+0.02+0.00-0.33+3.72-

Board & Governance of Sms Pharmaceuticals Limited

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Sms Pharmaceuticals Limited has 8 directors - 4 independent and 2 executive. The board is chaired by Ramesh Babu Potluri.

DirectorPositionOn board sinceListed boards
Ramesh Babu Potluri Executive Director · MD · Chairperson 1990-08-30 1
Shravan Kudaravalli Non-Executive - Independent Director 2018-09-20 1
Sarvepalli Srinivas Non-Executive - Independent Director 2019-08-12 1
Vamsi Krishna Potluri Executive Director 2020-06-05 1
Trilok Potluri Non-Executive - Non Independent Director 2024-08-12 1
Sunkara Venkata Satya Shiva Prasad Non-Executive - Non Independent Director 2024-08-12 2
Suresh Kumar Gangavarapu Non-Executive - Independent Director 2024-08-12 1
Shanti Sree Bolleni Non-Executive - Independent Director 2024-08-12 5
Board Committees
CommitteeMembers
Audit Committee Shravan Kudaravalli (Chairperson), Suresh Kumar Gangavarapu, Vamsi Krishna Potluri, Shanti Sree Bolleni
Nomination and remuneration committee Shanti Sree Bolleni (Chairperson), Suresh Kumar Gangavarapu, Sunkara Venkata Satya Shiva Prasad
Stakeholders Relationship Committee Sunkara Venkata Satya Shiva Prasad (Chairperson), Trilok Potluri, Sarvepalli Srinivas, Shanti Sree Bolleni
Risk Management Committee Ramesh Babu Potluri (Chairperson), Vamsi Krishna Potluri, Shravan Kudaravalli
Corporate Social Responsibility Committee Ramesh Babu Potluri (Chairperson), Shravan Kudaravalli, Sarvepalli Srinivas

Group Structure of Sms Pharmaceuticals Limited

Sms Pharmaceuticals Limited has 1 associated company. This group structure data is as of FY 2024. The corporate group structure reflects Sms Pharmaceuticals Limited's business expansion strategy and organizational complexity.

1
Associated companies

Charges & Borrowings of Sms Pharmaceuticals Limited

Open charges
₹600.28 Cr
Satisfied charges
₹640.7 Cr
Breakdown by lending institutions
Others₹232.39 Cr
State Bank of India₹197.03 Cr
Idbi Bank Limited₹136.70 Cr
Axis Bank Limited₹34.15 Cr
Mid - West Leasing Ltd.₹0.01 Cr
Latest charge details
DateLenderAmountStatus
22 Oct 2025 Axis Bank Limited ₹34.15 Cr Open
14 Feb 2024 Others ₹100 Cr Open
24 Jan 2023 Idbi Bank Limited ₹25 Cr Open
08 Mar 2022 Others ₹16.09 Cr Open
25 Feb 2022 State Bank of India ₹23.2 Cr Open

Total charge records: 63 View all charges

Employees and EPFO Compliance at Sms Pharmaceuticals Limited

Sms Pharmaceuticals Limited has a workforce of 1,193 employees as of Mar 23, 2024.

Employee count
1,193
Active EPFO establishments
2
Employee growth
8.55%
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Employee Count & EPFO Data of Sms Pharmaceuticals Limited

Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.

Monthly employee headcount & PF contributions
EPFO establishment details & ECR filing status
Year-wise workforce analytics & attrition trends
PF exemption, coverage & compliance verification

GST Compliance of Sms Pharmaceuticals Limited

XX%
Compliant
GSTR-1
GSTR-3B
GSTR-9
MH
KA
UP
TN
TS

GSTIN & GST Filing Data of Sms Pharmaceuticals Limited

Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.

GSTIN registrations & state-wise presence
Filing compliance - GSTR-1, GSTR-3B, GSTR-9
HSN/SAC codes with goods & services details
Taxpayer type, jurisdiction & business constitution

Credit Ratings, Litigation & Regulatory Alerts for Sms Pharmaceuticals Limited

Credit rating
AAA
AA+
AA
AA-
! !
2015 2017 2019 2021 2023
Litigation
District Court 35
High Court 45
Supreme Court 0
NCLT / NCLAT 0
Pending
Disposed
Regulatory alerts
GSTIN Cancelled
Andhra Pradesh
GSTIN Cancelled
Telangana (on application)
EPFO Delay
12 months delay - Haryana
Violations via Directors
20 MCA + 19 Bank defaults

Credit Ratings, Legal Cases & Regulatory Alerts of Sms Pharmaceuticals Limited

Access complete credit rating history, litigation records, regulatory alerts, and compliance data.

Credit rating history across CARE, ICRA, Brickwork & India Ratings
Instrument-wise ratings, outlook & action timeline
Court-wise litigation (District, High Court, Supreme Court, NCLT)
Group company & common directorship litigation
Statutory compliance alerts (GSTIN, EPFO, ROC)
Director & company violations (MCA, SEBI, Banks, BSE/NSE)

MSME Payment Delays by Sms Pharmaceuticals Limited

MSME Payment Delays by Sms Pharmaceuticals Limited

Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.

Amounts outstanding to MSME suppliers
Delay periods & reasons for delayed payments
Half-yearly MSME-1 filing history
Vendor-payment behaviour as a counterparty risk signal

Subsidiaries & Group Companies of Sms Pharmaceuticals Limited

Subsidiaries & Group Companies of Sms Pharmaceuticals Limited

See the full corporate group - holding company, subsidiaries, associates and joint ventures of Sms Pharmaceuticals Limited with ownership details.

Holding & parent company details
Subsidiaries & step-down subsidiaries with % holding
Associates & joint ventures with partner details
Investments in other entities year-on-year

MCA Filings & Documents of Sms Pharmaceuticals Limited

MCA Filings & Documents of Sms Pharmaceuticals Limited

Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.

Incorporation documents, MoA & AoA
Annual returns (MGT-7) & financial statements (AOC-4)
Charge filings (CHG-1, CHG-4) & resolutions
Complete document index with filing dates

Recent Activity on Sms Pharmaceuticals Limited

Charges
11 Nov 2025
A charge with Others of Rs. 40.00 Cr registered on 24 Jun 2016 with Charge ID 100035079 was modified on 11 Nov 2025.
Charges
11 Nov 2025
A charge with State Bank Of India of Rs. 173.83 Cr registered on 11 May 1989 with Charge ID 90260758 was modified on 11 Nov 2025.
Charges
28 Oct 2025
A charge registered on 02 Nov 2023 via Charge ID 100819428 with Others was fully satisfied on 28 Oct 2025.
Charges
22 Oct 2025
A charge with Axis Bank Limited amounted to Rs. 34.15 Cr with Charge ID 101182903 was registered on 22 Oct 2025.
Activity
29 Sep 2025
Sms Pharmaceuticals Limited last Annual general meeting of members was held on 29 Sep 2025 as per latest MCA records.
Activity
31 Mar 2025
Sms Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad.

Frequently Asked Questions about Sms Pharmaceuticals Limited

Sms Pharmaceuticals Limited is an active public limited company in the pharma sector based in Hyderabad, Telangana, India. It was incorporated on 14 December 1987 (39+ years old) and is registered under CIN L24239TG1987PLC008066. Listed on BSE: 532815 and NSE: SMSPHARMA. The company has 1,193 employees.

Sms Pharmaceuticals Limited reported revenue of ₹788.97 Cr for FY 2025 (up 11.00% YoY).

The current directors of Sms Pharmaceuticals Limited are:

The primary industry of Sms Pharmaceuticals Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.

Yes. Sms Pharmaceuticals Limited is listed on both BSE (code: 532815) and NSE (symbol: SMSPHARMA).

Sms Pharmaceuticals Limited can be reached at the registered office: Plot No. 72 H.No: 8 – 2 – 3343&4 Road No. 5 Opp. Sbi Executive Enclave Banjara Hill, S, Hyderabad, Telangana, India – 500034, or through the website smspharma.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available